HD LifeSciences’ received FDA 510(k) clearance for its Hive-C IBFD, a system of interbody devices for ACDF procedures. The Hive-C implant system will be commercially available in July 2018.The devices are based on HD’s patented, additive-manufactured Soft Titanium® technology, designed to provide optimum stiffness, ideal imaging and a bioactive surface treatment to support fusion.
Hive-C implants are offered in a range of sizes and geometries to accommodate patient anatomy and surgical approach, and are sterile packed.
Ian Helmar, Chief Product Officer, said: “HD LifeSciences is excited to serve the high demand for the benefits of Soft Titanium® technology in the cervical market. We look forward to expanding our product offering with additional regulatory clearances by the end of the year”.